Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP)
Purpura, Thrombocytopenic, Idiopathic
Quality of Life
Recombinant Fusion Proteins
Romiplostim significantly reduced parental burden in this study. Whether the same and/or additional improvements in HRQoL would be demonstrated by a larger, longer study of romiplostim-treated children with ITP remains to be determined. Pediatr Blood Cancer 2012; 58: 395-398. © 2011 Wiley Periodicals, Inc.
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency